In the wake of their Elelyso approval, Pfizer may price Sanofi/Genzyme's blockbuster Cerezyme out of the market. But will other big Pharma also move to compete on price? The business rationale is real, so we discuss if now is the time for change.

In this exclusive eyeforpharma briefing document we air the debate by taking a historical look at the dwindling returns from ‘me-too’ drugs, and comment on why the industry continues to either: terminate such drug programs in development or launch at a non-competitive price.

You can download this free piece of content here

Along with expert discussion we have the most complete listing of 2012 Q1 sales for the 96 potential blockbusters, replete with their mechanism of action. So you can see for yourself what the lack of price competition may mean to your business.

I hope you find it useful,

Best,

Theo Fellgett

VP North America | eyeforpharma

theo@eyeforpharma.com

Office: 201.234.4802